Elicio Therapeutics (ELTX) Capital Leases (2021 - 2022)
Elicio Therapeutics (ELTX) reported Capital Leases of $168000.0 for Q4 2022, down 28.51% on a YoY basis from $235000.0 in Q4 2021, and down 9.68% quarter-over-quarter from $186000.0 in Q3 2022.
Elicio Therapeutics (ELTX) Capital Leases (2021 - 2022) Analysis & Trends
Elicio Therapeutics has reported Capital Leases for 2 years, with the latest figure at $168000.0 in Q4 2022.
- For the quarter ending Q4 2022, Capital Leases fell 28.51% year-over-year to $168000.0; the trailing twelve-month figure through Dec 2022 stood at $168000.0 (down 28.51% YoY), and the FY2022 full-year result was $168000.0, down 28.51% from the prior year.
- Capital Leases for Q4 2022 stood at $168000.0, down from $186000.0 in the prior quarter.
- The five-year high for Capital Leases was $235000.0 in Q4 2021, with the low at $168000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Elicio Therapeutics | 70.12 Mn | 55.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 168,000.00 |
| Sep 30, 2022 | 186,000.00 |
| Jun 30, 2022 | 202,000.00 |
| Mar 31, 2022 | 219,000.00 |
| Dec 31, 2021 | 235,000.00 |